Beijing Beilu Pharmaceutical (300016) Fundamentals 2026 — P/E 33.8x, Revenue Analysis | SniperIQ
Beijing Beilu Pharmaceutical (300016) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥4.4B, trading at ¥7.56 on the SHZ. This SniperIQ fundamentals page covers Beijing Beilu Pharmaceutical's valuation (P/E 33.8x, P/B 1.8x), profitability (net margin 9.9%), revenue (¥1.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Beijing Beilu Pharmaceutical's market cap?
Beijing Beilu Pharmaceutical (300016) has a market capitalization of approximately ¥4.4B, trading at ¥7.56 on the SHZ. Market cap moves with the live share price.
What is Beijing Beilu Pharmaceutical's P/E ratio?
Beijing Beilu Pharmaceutical's trailing twelve-month P/E ratio is 33.8x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Beijing Beilu Pharmaceutical?
Beijing Beilu Pharmaceutical runs a net profit margin of 9.9%, a gross margin of 45.5%, and an operating margin of 7.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Beijing Beilu Pharmaceutical generate?
Beijing Beilu Pharmaceutical reported revenue of ¥1.2B for fiscal year 2025, with net income of ¥93M and earnings per share (EPS) of 0.18. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Beijing Beilu Pharmaceutical pay a dividend?
Beijing Beilu Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Beijing Beilu Pharmaceutical financially healthy?
Beijing Beilu Pharmaceutical carries a debt-to-equity ratio of 0.28x and a current ratio of 2.39x, with a market beta of 0.28. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Beijing Beilu Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Beijing Beilu Pharmaceutical (300016) the key facts are: market cap ¥4.4B, P/E 33.8x, revenue ¥1.2B, 52-week range 7.08-11.98. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Beijing Beilu Pharmaceutical's full fundamentals live
Get Beijing Beilu Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.